Alian Alrasheedy

Dr. Alian Alrasheedy

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2014 in Saudi Pharmaceutical Journal
Verified
Journal Article
Open access
AHAzmi Hassali
Azmi Hassali
AAAlian Alrasheedy
Alian Alrasheedy
AMAndrew McLachlan
Andrew McLachlan
TNTuan Anh Nguyen
Tuan Anh Nguyen
Saleh Karamah AL-TamimiSaleh Karamah AL-Tamimi
Saleh Karamah AL-Tamimi
HAHisham Aljadhey
Hisham Aljadhey
Generic medicines are clinically interchangeable with original brand medicines and have the same quality, efficacy and safety profiles. They are, nevertheless, much cheaper in price. Thus, while providing the same therapeutic outcomes, generic medicines lead to substantial savings for healthcare systems. Therefore, the quality use of generic medicines is promoted in many countries. In this paper, we reviewed the role of generic medicines in healthcare systems and the experiences of promoting the use of generic medicines in eight selected countries, namely the United States (US), the United Kingdom (UK), Sweden, Finland, Australia, Japan, Malaysia and Thailand. The review showed that there are different main policies adopted to promote generic medicines such as generic substitution in the US, generic prescribing in the UK and mandatory generic substitution in Sweden and Finland. To effectively and successfully implement the main policy, different complementary policies and initiatives were necessarily introduced. Barriers to generic medicine use varied between countries from negative perceptions about generic medicines to lack of a coherent generic medicine policy, while facilitators included availability of information about generic medicines to both healthcare professionals and patients, brand interchangeability guidelines, regulations that support generic substitution by pharmacists, and incentives to both healthcare professionals and patients.

23 December 2019 in Expert Review of Anti-infective Therapy
Verified
Journal Article
Closed access
AAAlian Alrasheedy
Alian Alrasheedy
MAMuath A. Alsalloum
Muath A. Alsalloum
FAFeras A. Almuqbil
Feras A. Almuqbil
MAMuaath A. Almuzaini
Muaath A. Almuzaini
BABandar S. Aba Alkhayl
Bandar S. Aba Alkhayl
MAMohammed Saif Anaam
Mohammed Saif Anaam
Objective: Dispensing of antibiotics without a prescription (DAwP) has been widely practised among community pharmacies in Saudi Arabia despite being illegal. However, in May 2018, the law and regulations were enforced alongside fines. Consequently, we wanted to evaluate the impact of these changes. Methods: A study was conducted among 116 community pharmacies in two phases. Pre-law enforcement phase between December 2017 and March 2018 and a post-law enforcement phase a year later. Each phase consisted of a cross-sectional questionnaire-based survey and a simulated client method (SCM). In the SCM, clients presented with either pharyngitis or urinary tract infections (UTI). In SCM, for each phase, all 116 pharmacies were visited with one of the scenarios. Results: Before the law enforcement, 70.7 % reported that DAwP was common with 96.6% and 87.7% of participating pharmacies dispensed antibiotics without a prescription for pharyngitis and UTI respectively. After the law enforcement, only 12.9% reported that DAwP is still a common practice, with only 12.1% and 5.2% dispensing antibiotics without prescriptions for pharyngitis and UTI respectively. Conclusion: law enforcement was effective. However, there is still further scope for improvement. This could include further educational activities with pharmacists, physicians and the public.

2 January 2020 in Expert Review of Pharmacoeconomics & Outcomes Research
Verified
Journal Article
Open access
BGBrian Godman
Brian Godman
HMHolly McCabe
Holly McCabe
TLTrudy Leong
Trudy Leong
DMDebjani Mueller
Debjani Mueller
AMAntony P. Martin
Antony P. Martin
Johanna Catharina MeyerJohanna Catharina Meyer
Johanna Catharina Meyer
Introduction: There are positive aspects regarding the prescribing of fixed dose combinations (FDCs) versus prescribing the medicines separately. However, these have to be balanced against concerns including increased costs and their irrationality in some cases. Consequently, there is a need to review their value among lower- and middle-income countries (LMICs) which have the greatest prevalence of both infectious and noninfectious diseases and issues of affordability. Areas covered: Review of potential advantages, disadvantages, cost-effectiveness, and availability of FDCs in high priority disease areas in LMICs and possible initiatives to enhance the prescribing of valued FDCs and limit their use where there are concerns with their value. Expert commentary: FDCs are valued across LMICs. Advantages include potentially improved response rates, reduced adverse reactions, increased adherence rates, and reduced costs. Concerns include increased chances of drug:drug interactions, reduced effectiveness, potential for imprecise diagnoses and higher unjustified prices. Overall certain FDCs including those for malaria, tuberculosis, and hypertension are valued and listed in the country’s essential medicine lists, with initiatives needed to enhance their prescribing where currently low prescribing rates. Proposed initiatives include robust clinical and economic data to address the current paucity of pharmacoeconomic data. Irrational FDCs persists in some countries which are being addressed.

1 October 2018 in Research in Social and Administrative Pharmacy
Verified
Journal Article
Closed access
SASuhaj Abdulsalim
Suhaj Abdulsalim
MUMazhuvancherry Kesavan Unnikrishnan
Mazhuvancherry Kesavan Unnikrishnan
MMMohan K. Manu
Mohan K. Manu
AAAlian Alrasheedy
Alian Alrasheedy
BGBrian Godman
Brian Godman
DMDonald Morisky
Donald Morisky

1 February 2018 in Saudi Pharmaceutical Journal
Verified
Journal Article
Open access
Abubakr Abdelraouf AlfadlAbubakr Abdelraouf Alfadl
Abubakr Abdelraouf Alfadl
AAAlian Alrasheedy
Alian Alrasheedy
MAMusaad S. Alhassun
Musaad S. Alhassun
Pharmacists have a unique opportunity to promote good health through assuring the quality use of medicines. One of the most important tools to achieve this is medication counseling. Counseling plays an important role in enhancing medication adherence and optimizing medication therapy. Therefore, for improving the quality of services delivered by community pharmacists, it is essential to assess the current situation of counseling services delivered to patients. To date, there is a paucity of data regarding the quality of counseling services delivered to patients in community pharmacies in Saudi Arabia. This study aims to fill this gap through evaluating the counseling skills and counseling content delivered by pharmacists in a sample of community pharmacies in Qassim region, Saudi Arabia. The study was conducted at eleven community pharmacies in Qassim region. A convenient sample of community pharmacies was chosen based on their willingness to participate. To gather information, a form was prepared based on the core and complementary drug use indicators for evaluation of drug use in healthcare settings developed by the WHO. The study was conducted through observing the counseling services performed by the community pharmacists who participated in the study. Two hundred and thirty-five forms were completed in eleven community pharmacies. A total of 44.4% of the counseling skills was found to be performed adequately, while only 20.1% of the counseling contents were performed adequately. The overall standard of medication counseling services provided to patients to improve usage of their medications, and consequently, their well-being was poor.

1 February 2021 in Journal of Telemedicine and Telecare
Verified
Journal Article
Closed access
PDF file
ATAyla M Tourkmani
Ayla M Tourkmani
TATurki J Alharbi
Turki J Alharbi
ARAbdulaziz M Bin Rsheed
Abdulaziz M Bin Rsheed
AAAlian Alrasheedy
Alian Alrasheedy
WAWedad Almadani
Wedad Almadani
AAAbdulaziz A Ibn Alshaikh
Abdulaziz A Ibn Alshaikh
Routine diabetes care changed during the COVID-19 pandemic due to precautionary measures such as lockdowns, cancellation of in-person visits, and patients’ fear of being infected when attending clinics. Because of the pandemic, virtual clinics were implemented to provide diabetes care. Therefore, we conducted this study to assess the impact of these virtual clinics on glycaemic control among high-risk patients with type 2 diabetes mellitus (DM). A prospective single-cohort pre-/post telemedicine care intervention study was conducted on 130 patients with type 2 DM attending a virtual integrated care clinic at a chronic Illness center in a family and community medicine department in Riyadh, Saudi Arabia during the COVID-19 pandemic. The mean age of the participants was 57 years (standard deviation (SD) = 12) and the mean (SD) duration of diabetes was 14 (7) years. Over a period of 4 months, the HbA1c decreased significantly from 9.98 ± 1.33 pre-intervention to 8.32 ± 1.31 post-intervention (mean difference 1.66 ± 1.29; CI = 1.43–1.88; P <0.001). In addition, most in-person care visits were successfully replaced, as most patients (64%) needed only one or two in-person visits during the 4-month period, compared with typically one visit every 1–2 weeks in the integrated care programme before the pandemic for this group of high-risk patients. The current study found a significant positive impact of telemedicine care on glycaemic control among high-risk patients with DM during the COVID-19 pandemic. Moreover, it showed that telemedicine could be integrated into diabetic care to successfully replace many of the usual in-person care visits. Consequently, health policy makers need to consider developing comprehensive guidelines in Saudi Arabia for telemedicine care to, ensure the quality of care and address issues such as financial reimbursement and patient information privacy.